학술논문
Essential medicine selection during the COVID-19 pandemic: Enabling access in uncharted territory
Document Type
Report
Author
Source
SAMJ South African Medical Journal. November, 2020, Vol. 110 Issue 11, p1077, 4 p.
Subject
Language
English
ISSN
0256-9574
Abstract
The COVID-19 pandemic requires urgent decisions regarding treatment policy in the face of rapidly evolving evidence. In response, the South African Essential Medicines List Committee established a subcommittee to systematically review and appraise emerging evidence, within very short timelines, in order to inform the National Department of Health COVID-19 treatment guidelines. To date, the subcommittee has reviewed 14 potential treatments, and made recommendations based on local context, feasibility, resource requirements and equity. Here we describe the rapid review and evidence-to-decision process, using remdesivir and dexamethasone as examples. Our experience is that conducting rapid reviews is a practical and efficient way to address medicine policy questions under pandemic conditions. S Afr Med J 2020;110(11):1077-1080. https://doi.org/10.7196/SAMJ.2020.vn0in.15271
The COVID-19 pandemic has posed unprecedented challenges for healthcare globally. Clinicians and policymakers have had to make urgent decisions regarding therapeutic interventions in the face of rapidly evolving evidence of [...]
The COVID-19 pandemic has posed unprecedented challenges for healthcare globally. Clinicians and policymakers have had to make urgent decisions regarding therapeutic interventions in the face of rapidly evolving evidence of [...]